• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Japan mulls approving AstraZeneca COVID vaccine for people 18 and over

firstwordpharmaJune 24, 2021

Tag: AstraZeneca , COVID-19 , Vaccine

According to sources, Japan is considering approving the use of AstraZeneca's COVID-19 vaccine for people aged 18 or over, as reported Kyodo News+ on Wednesday.

Japan mulls approving AstraZeneca COVID vaccine for people 18 and over

The Ministry of Health, Labor and Welfare granted fast-track approval for the vaccine in May and is already planning to approve it for people aged 60 or older.

An expert panel of the health ministry will consider the eligible age range for the vaccine on June 30.

Previous:Orion Biotechnology Secures $11.5M Series A Financing

Next:Arcus says early data for anti-TIGIT domvanalimab combos look good, but mum on details

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Japan mulls approving AstraZeneca COVID vaccine for people 18 and over | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

vaccine bioreactor system

vaccine bioreactor system
Recombinant B-Subunit/Whole Cell Cholera Vaccine(Enteric-coated Capsule)

Recombinant B-Subunit/Whole Cell Cholera Vaccine(Enteric-coated Capsule)
IPV(Inactivated Poliovirus Vaccine)

IPV(Inactivated Poliovirus Vaccine)
Rabies Vaccine(Vero Cell)for Human use

Rabies Vaccine(Vero Cell)for Human use
Ruminant Vaccine Series

Ruminant Vaccine Series
Real Time Multiplex RT-PCR Kit (for COVID-19)

Real Time Multiplex RT-PCR Kit (for COVID-19)
Swine Vaccine Series

Swine Vaccine Series
Recombinant Hepatitis B Vaccine(Saccharomyces Cerevisiae)

Recombinant Hepatitis B Vaccine(Saccharomyces Cerevisiae)
Enterovirus Type 71 Vaccine, Inactivated (Human Diploid Cell)

Enterovirus Type 71 Vaccine, Inactivated (Human Diploid Cell)
Vi Polysaccharide Typhoid Vaccine

Vi Polysaccharide Typhoid Vaccine

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service